Literature DB >> 26064296

An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative.

Peiman Haddad1, Sohrab Shazadi2, Farhad Samiei1, Homayoun Hadizadeh Kharrazi3, Morteza Tabatabaeefar4, Afshin Rakhsha4, Mohammad Faranoosh5, Mohammad Torabi-Nami6, Ali Dadras7, Atieh Liaghi7, Leila Nafarieh8.   

Abstract

Research and practice of neuro-oncology compiles clinical neuroscience expertise from neurosurgery, radiation oncology, neuroradiology, medical oncology, neuropathology and related disciplines to optimize planning and therapy in central nervous system malignancies. Such an interdisciplinary context prompted health-care providers from all related disciplines to establish the Neuro-Oncology Scientific Club (NOSC) in Iran and let it flourish since 3 years ago. With the advent of advanced technologies and through continued share of experience, NOSC members have tried to provide more integrated diagnoses and therapeutic care to brain tumor patients across the country. NOSC activities revolve around some key tenets including dissemination of education and updates, facilitation of institutional collaborations; data registry and patients' awareness. By virtue of recent insights on molecular characterization of brain tumors such as codeletion of chromosomes 1p and 19q in anaplastic gliomas and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma, a range of translational research is being followed within NOSC. The most recent NOSC meeting which was held in Tehran, recapitulated main advances and dealt with the current debates on functional neurosurgery, biological markers and neuroimaging, risk prediction models in high grade gliomas and clinical issues in pediatric neuro-oncology. This article gives an overview of current hotspots in neuro-oncology research and practice which are pursued within NOSC.

Entities:  

Keywords:  Interdisciplinary; Iran; NOSC; brain tumors; neuro-oncology

Year:  2015        PMID: 26064296      PMCID: PMC4443130     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  50 in total

1.  Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.

Authors:  V A Levin; J H Uhm; K A Jaeckle; A Choucair; P J Flynn; M D Prados; J M Bruner; S M Chang; A P Kyritsis; M J Gleason; K R Hess
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

2.  OncoCase: interdisciplinary case based teaching in Neuro-Oncology based on the campus platform.

Authors:  Martin Boeker; Christine Müller; Rüdiger Klar; Johannes Lutterbach
Journal:  AMIA Annu Symp Proc       Date:  2005

Review 3.  Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

Authors:  L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

4.  Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.

Authors:  Hemi Malkki
Journal:  Nat Rev Neurol       Date:  2014-03-18       Impact factor: 42.937

5.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.

Authors:  Thierry Gorlia; Jean-Yves Delattre; Alba A Brandes; Johan M Kros; Martin J B Taphoorn; Mathilde C M Kouwenhoven; H J J A Bernsen; Marc Frénay; Cees C Tijssen; Denis Lacombe; Martin J van den Bent
Journal:  Eur J Cancer       Date:  2013-07-26       Impact factor: 9.162

8.  Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?

Authors:  Pakzad Fathpour; Nina Obad; Heidi Espedal; Daniel Stieber; Olivier Keunen; Per Ø Sakariassen; Simone P Niclou; Rolf Bjerkvig
Journal:  Neuro Oncol       Date:  2014-05       Impact factor: 12.300

Review 9.  The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.

Authors:  Hans Skovgaard Poulsen; Thomas Urup; Signe Regner Michaelsen; Mikkel Staberg; Mette Villingshøj; Ulrik Lassen
Journal:  Cancer Manag Res       Date:  2014-09-26       Impact factor: 3.989

10.  Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group.

Authors:  Ji Hyun Chang; Chae-Yong Kim; Byung Se Choi; Yu Jung Kim; Jae Sung Kim; In Ah Kim
Journal:  J Korean Neurosurg Soc       Date:  2014-01-31
View more
  1 in total

Review 1.  A comprehensive approach in high-grade glioma management: position statement from the Neuro-Oncology Scientific Club (NOSC), Shiraz, Iran.

Authors:  Mansour Ansari; Ahmad Mosalaei; Niloufar Ahmadloo; Alireza Rasekhi; Bita Geramizadeh; Ali Razmkon; Kazem Anvari; Mohammad Afarid; Ali Dadras; Leila Nafarieh; Mohammad Mohammadianpanah; Hamid Nasrolahi; Seyed Hasan Hamedi; Shapour Omidvari; Mohammad Nami
Journal:  Ger Med Sci       Date:  2017-02-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.